ReviewHeliyon2022
A comprehensive review on the diverse pharmacological perspectives of
Review in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 102 citations in OpenAlex.
- Article
- Review
- The Multifaceted Benefits of Triphala: Uncovering Phytochemical and Pharmacological Properties From Antiquity to Modern Times.Chemistry & biodiversity · 2026Review
- A comprehensive review on herbal approaches for treatment of urinary tract infections: Scope and challenges.Journal of pharmaceutical analysis · 2026Review
- Molecular insights of a Unani formulation in targeting fibrosis-associated diseases.Frontiers in pharmacology · 2026Review
- Comparative Effectiveness of Triphala and Conventional Root Canal Irrigants in Primary Teeth: A Systematic Review.Cureus · 2025Review
- Unlocking the Therapeutic Potential of Ellagitannins: A Comprehensive Review of Key Representatives.Molecules (Basel, Switzerland) · 2025Review
- Article
- Comparative analysis of Chinese classical prescriptions and global traditional polyherbal formulations: insights from the database of global polyherbal formulation (GPFD).Chinese medicine · 2025Article
- Phytotherapeutic insights into hyperuricemia: a mechanistic and clinical perspective.Inflammopharmacology · 2025Review
- Chebulagic acid ameliorates DSS-induced colitis in mice by improving oxidative stress, inflammation and the gut microbiota.American journal of translational research · 2025Article
- Identification of Potential Inhibitors from Medicinal Plant-based Phytochemicals for the Influential C4 Target of Diabetic Retinopathy by Molecular Docking Studies.Current pharmaceutical design · 2025Article
- Triphala's characteristics and potential therapeutic uses in modern health.International journal of physiology, pathophysiology and pharmacology · 2025Review
- Antiplasmodial Screening of Phikud Navakot Formulation and In Vivo Evaluation, Toxicity, and Phytochemical Profiling of the PotentScientifica · 2025Article
- Herbal Interactions with Cardiac Medications: A Comprehensive Review of Potential Interactions between Herbal Drugs and Commonly Prescribed Cardiac Medications.Current drug safety · 2025Review
- Dual intervention of Boeravinone B and Chebulinic Acid mitigates BHT-Induced toxicity in HepG2 cells: modulating apoptosis and autophagy.Scientific reports · 2024Article
- Comprehensive Review on Fruit ofMolecules (Basel, Switzerland) · 2024Review
- Natural product-based treatment potential for type 2 diabetes mellitus and cardiovascular disease.World journal of diabetes · 2024Article
- Study on Quality Characteristic of Chebulae Fructus and Its Adulterants and Degradation Pathway of Hydrolyzable Tannins.Molecules (Basel, Switzerland) · 2024Article
- The potential ofFrontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.